For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Antibodies are fundamental to proteomic research and are widely-used immunodetection reagents. Recent concerns over scientific reproducibility as a result of non-specific, inconsistent antibody performance1 have focused efforts to thoroughly validate antibody reagents during development and before use in end-applications.
Knockout (KO) cell lines, where the target of interest has been edited out of the genome of human cell lines using CRISPR-Cas9, provide a permanent KO and a “gold standard” scalable model. Specific antibodies do not detect their target in validated KO cell lines and therefore serve as a true negative control.
In order to make a significant impact on improving the current reproducibility crisis, KO validation needs to be carried out at a scale relevant to the life sciences industry, which can be expedited by use of full, end-to-end automation for high-throughput (HT) KO cell line generation.